Safety and efficacy of rapid (1,000 mg in 1 hr) intravenous iron dextran for treatment of maternal iron deficient anemia of pregnancy

被引:36
|
作者
Wong, Lee [1 ]
Smith, Samuel [1 ]
Gilstrop, Marisa [2 ]
Derman, Richard [2 ]
Auerbach, Sarah [3 ]
London, Nicola [1 ]
Lenowitz, Steven [1 ]
Bahrain, Huzefa [4 ]
McClintock, Jessica [1 ]
Auerbach, Michael [5 ]
机构
[1] MedStar Franklin Sq Med Ctr, Dept Obstet & Gynecol, Baltimore, MD USA
[2] Christiana Care Hlth Syst, Dept Obstet & Gynecol, Newark, DE USA
[3] West Virginia Sch Osteopath Med, Lewisburg, WV USA
[4] Auerbach Hematol & Oncol, Baltimore, MD USA
[5] Georgetown Univ, Sch Med, Dept Med, Washington, DC USA
关键词
FERRIC CARBOXYMALTOSE; ORAL IRON; WEIGHT; SUCROSE; HEMOGLOBIN;
D O I
10.1002/ajh.24361
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Maternal iron deficiency anemia (IDA) is associated with risk of adverse perinatal outcomes. Oral iron is recommended to reverse anemia, but has gastrointestinal toxicity and frequent non-adherence. Intravenous (IV) iron is reserved for intolerance of, or unresponsiveness to, oral therapy, malabsorption, and severe anemia (1% with hemoglobin [Hgb] levels <7 g/dL). With rare (<100 per one million) adverse events (AEs) ability to infuse a sufficient dose of low molecular weight iron dextran (LMWID) over 60 min, LMWID is an attractive option. This study demonstrated safety and efficacy of rapid IV infusion of 1,000 mg LMWID to gravidas with moderate to severe IDA. An observational treatment study of 1,000 mg LMWID administered over 1 hr for IDA in 189 consecutive, unselected second and third trimester gravidas after oral iron failure was conducted. All received a test dose of 25 mg LMWID and were monitored for AEs during the 60-min infusion. No premedication was administered unless more than one drug allergy or asthma was present in which case IV methylprednisolone was administered. All were followed through pregnancy and delivery. Monitored parameters included Hgb, mean corpuscular volume, serum ferritin, and percent transferrin saturation. About 189 subjects received 1,000 mg LMWID. No serious AEs occurred. About 2% experienced transient infusion reactions. Hgb improved by 1-1.9 g/dL in 82% and >= 2 g/dL in 24%. Second trimester treatment was not associated with greater Hgb improvement than third trimester treatment. Anemia resolved in 95%. Administration of a single large dose of IV LMWID was effective, safe, and convenient. (C) 2016 Wiley Periodicals, Inc.
引用
收藏
页码:590 / 593
页数:4
相关论文
共 39 条
  • [31] The Patient in Focus- a non-interventional Study on Treatment Success in Patients with Iron Deficiencty/- Anaemia who received a Starting Dose of 1,000 mg Eisencarboxymaltose
    Schnellhammer, C.
    Habermehl, V.
    INTERNIST, 2016, 57 : S17 - S17
  • [32] Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for the treatment of preoperative anemia in patients with menorrhagia: An open-label, multicenter, randomized study
    Lee, Sanghoon
    Ryu, Ki-Jin
    Lee, Eun Sil
    Lee, Keun Ho
    Lee, Jeong Jae
    Kim, Tak
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2019, 45 (04) : 858 - 864
  • [33] Safety and Efficacy of Long-Term Treatment of Type 1 Plasminogen Deficient Patients With Intravenous Plasminogen Replacement Therapy
    Shapiro, Amy D.
    Mcdaniel, Heather
    Decker, Robert W.
    Nakar, Charles
    Lorber, Jeremy
    Thukral, Neelam
    Parker, Joseph M.
    Thibaudeau, Karen
    HAEMOPHILIA, 2025,
  • [34] Safety and Efficacy of Rapid Titration Using 1mg Doses of Intravenous Hydromorphone in Emergency Department Patients With Acute Severe Pain: The "1+1" Protocol
    Chang, Andrew K.
    Bijur, Polly E.
    Campbell, Caron M.
    Murphy, Mary K.
    Gallagher, E. John
    ANNALS OF EMERGENCY MEDICINE, 2009, 54 (02) : 221 - 225
  • [35] DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-CENTER EVALUATION OF RESTLESS LEGS SYNDROME (RLS) TREATMENT WITH A 1,000 MG OF IV IRON (FERRIC CABOXYMALTOSE-FCM)
    Allen, R. P.
    Butcher, A.
    Du, W.
    SLEEP, 2009, 32 : A294 - A295
  • [36] Maternal efficacy, safety, and pregnancy outcomes with degludec vs detemir in the treatment of pregnant women with type 1 diabetes: an international, multicentre, randomised trial
    Mathiesen, E. R.
    Corcoy, R.
    Dunne, F.
    Ekelund, M.
    Feig, D. S.
    Hod, M.
    Jia, T.
    Kalyanam, B.
    Kar, S.
    Kautzky-Willer, A.
    Damm, P.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 11 - 11
  • [37] Efficacy and Safety of 400 and 800mg Etodolac vs. 1,000mg Paracetamol in Acute Treatment of Migraine: A Randomized, Double-blind, Crossover, Multicenter, Phase III Clinical Trial
    Ozturk, Vesile
    Ertas, Mustafa
    Baykan, Betul
    Sirin, Hadiye
    Ozge, Aynur
    PAIN PRACTICE, 2013, 13 (03) : 191 - 197
  • [38] The Mig-Etol Study Group. Efficacy and Safety of 400 and 800 mg Etodolac vs. 1,000 mg Paracetamol in Acute Treatment of Migraine: A Randomized, Double-blind, Crossover, Multicenter, Phase III Clinical Trial (vol 13, pg 191, 2013)
    Ozturk, V
    Ertas, M.
    Baykan, B.
    Sirin, H.
    Ozge, A.
    PAIN PRACTICE, 2013, 13 (08) : 673 - 673
  • [39] Superior efficacy and safety of 1-year treatment with monthly calcifediol 0.266 mg soft capsules compared to monthly cholecalciferol 25,000 IU and effect of calcifediol withdrawal in 25(OH)D levels
    Luis Perez-Castrillon, Jose
    Duenas-Laita, Antonio
    del Pino-Montes, Javier
    Hernandez-Herrero, Gonzalo
    Garcia-Bea, Aintzane
    Pamela Chinchilla, Sandra
    JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 : 195 - 195